In addition, a correlation between IGF‐1R and downstream PI3K pathway activation was reported in drug resistance (Fox et al., 2011; Gallardo et al., 2012; Leroy et al., 2016), and IGF‐1R and PI3K dual treatments act synergistically in targeting breast cancer cells (Ayub et al., 2015). Here, PIK3CA is linked to breast carcinoma.